Cargando…

A meta-analysis of efficacy and safety of doripenem for treating bacterial infections

OBJECTIVE: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. METHODS: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated int...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Xiao-Yu, Hu, Ting-Ting, Zhou, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425342/
https://www.ncbi.nlm.nih.gov/pubmed/25636188
http://dx.doi.org/10.1016/j.bjid.2014.10.010
_version_ 1784778427106066432
author Qu, Xiao-Yu
Hu, Ting-Ting
Zhou, Wei
author_facet Qu, Xiao-Yu
Hu, Ting-Ting
Zhou, Wei
author_sort Qu, Xiao-Yu
collection PubMed
description OBJECTIVE: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. METHODS: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2. RESULTS: Compared with empirical antimicrobial agents on overall treatment efficacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR] = 1.26, 95% confidence interval [CI] 0.93–1.69, p = 0.13; for clinical modified intent-to-treatment population, OR = 0.88, 95% CI 0.55–1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90–1.50, p = 0.26; for microbiological modified intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81–1.20, p = 0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modified intent-to-treatment population (for incidence of AEs, OR = 1.10, 95% CI 0.90–1.35, p = 0.33; for all-cause mortality, OR = 1.08, 95% CI 0.77–1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efficacy and safety. CONCLUSION: From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment.
format Online
Article
Text
id pubmed-9425342
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94253422022-08-31 A meta-analysis of efficacy and safety of doripenem for treating bacterial infections Qu, Xiao-Yu Hu, Ting-Ting Zhou, Wei Braz J Infect Dis Original Article OBJECTIVE: The aim of this article is to compare the efficacy and safety of doripenem for bacterial infections. METHODS: We included six randomized clinical trials identified from PubMed and Embase up to July 31, 2014. The included trials compared efficacy and safety of doripenem for complicated intra-abdominal infections, complicated urinary tract infection, nosocomial pneumonia, and acute biliary tract infection. The meta-analysis was carried on by the statistical software of Review Manager, version 5.2. RESULTS: Compared with empirical antimicrobial agents on overall treatment efficacy, doripenem was associated with similar clinical and microbiological treatment success rates (for the clinical evaluable population, odds ratio [OR] = 1.26, 95% confidence interval [CI] 0.93–1.69, p = 0.13; for clinical modified intent-to-treatment population, OR = 0.88, 95% CI 0.55–1.41, p = 0.60; for microbiology evaluable population, OR = 1.16, 95% CI 0.90–1.50, p = 0.26; for microbiological modified intent-to-treatment (m-mITT), OR = 0.98, 95% CI 0.81–1.20, p = 0.87). We compared incidence of adverse events and all-cause mortality to analyze treatment safety. The outcomes suggested that doripenem was similar to comparators in terms of incidence of adverse events and all-cause mortality on modified intent-to-treatment population (for incidence of AEs, OR = 1.10, 95% CI 0.90–1.35, p = 0.33; for all-cause mortality, OR = 1.08, 95% CI 0.77–1.51, p = 0.67). In nosocomial pneumonia and ventilator-associated pneumonia treatment, doripenem was not inferior to other antibacterial agents in terms of efficacy and safety. CONCLUSION: From this meta-analysis, we can conclude that doripenem is as valuable and well-tolerated than empirical antimicrobial agents for complicated intra-abdominal infections, complicated urinary tract infection, acute biliary tract infection and nosocomial pneumonia treatment. Elsevier 2015-01-27 /pmc/articles/PMC9425342/ /pubmed/25636188 http://dx.doi.org/10.1016/j.bjid.2014.10.010 Text en © 2015 Elsevier Editora Ltda. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Qu, Xiao-Yu
Hu, Ting-Ting
Zhou, Wei
A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
title A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
title_full A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
title_fullStr A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
title_full_unstemmed A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
title_short A meta-analysis of efficacy and safety of doripenem for treating bacterial infections
title_sort meta-analysis of efficacy and safety of doripenem for treating bacterial infections
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425342/
https://www.ncbi.nlm.nih.gov/pubmed/25636188
http://dx.doi.org/10.1016/j.bjid.2014.10.010
work_keys_str_mv AT quxiaoyu ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections
AT hutingting ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections
AT zhouwei ametaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections
AT quxiaoyu metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections
AT hutingting metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections
AT zhouwei metaanalysisofefficacyandsafetyofdoripenemfortreatingbacterialinfections